文章：

免疫检查点抑制剂在可切除非小细胞肺癌治疗中的应用价值

The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer

原文发布日期：25 July 2025

DOI: 10.3390/cancers17152462

类型: Article

开放获取: 是

英文摘要：

Immune checkpoint inhibitors (ICIs) are approved in at least one line of therapy for most patients with advanced non-small cell lung cancer (NSCLC) without EGFR/ALK alterations and have improved survival for a subset of patients. Adjuvant, neoadjuvant, and perioperative therapy for resectable NSCLC carries the hope of more broadly increased cure rates for patients with resectable lung cancers. This review summarizes the current state of multimodality management, including ICIs, for resectable NSCLC. A literature search of PubMed and Scopus identified phase II and III clinical trials including ICIs in patients with resectable NSCLC. No level 1 evidence guides the clinician in choosing between the available neoadjuvant and perioperative approaches.

摘要翻译： 

免疫检查点抑制剂（ICIs）已被批准用于大多数无EGFR/ALK基因突变的晚期非小细胞肺癌（NSCLC）患者的至少一线治疗，并显著提高了部分患者的生存率。针对可切除NSCLC的辅助治疗、新辅助治疗及围手术期治疗，为提升可切除肺癌患者的整体治愈率带来了希望。本综述总结了当前可切除NSCLC的多模式治疗（包括ICIs）现状。通过对PubMed和Scopus数据库的文献检索，筛选出涉及可切除NSCLC患者使用ICIs的II期和III期临床试验。目前尚无一级证据指导临床医生在现有新辅助治疗与围手术期治疗方案中作出选择。

原文链接：

The Utility of Immune Checkpoint Inhibition in the Management of Resectable Non-Small Cell Lung Cancer